Compare Shanghai Henlius Biotech, Inc. with Similar Stocks
Dashboard
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 5.46%
- Poor long term growth as Operating profit has grown by an annual rate 23.63% of over the last 5 years
- The company is Net-Debt Free
2
With ROE of 23.84%, it has a Very Expensive valuation with a 6.67 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
HKD 24,485 Million ()
28.00
NA
0.00%
0.69
20.41%
5.55
Revenue and Profits:
Net Sales:
1,586 Million
(Quarterly Results - Dec 2023)
Net Profit:
149 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.08%
0%
-2.08%
6 Months
10.89%
0%
10.89%
1 Year
67.65%
0%
67.65%
2 Years
275.53%
0%
275.53%
3 Years
457.09%
0%
457.09%
4 Years
318.14%
0%
318.14%
5 Years
74.69%
0%
74.69%
Shanghai Henlius Biotech, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
56.45%
EBIT Growth (5y)
23.63%
EBIT to Interest (avg)
-4.03
Debt to EBITDA (avg)
2.65
Net Debt to Equity (avg)
0.91
Sales to Capital Employed (avg)
0.73
Tax Ratio
3.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.46%
ROE (avg)
10.54%
Valuation key factors
Factor
Value
P/E Ratio
28
Industry P/E
Price to Book Value
6.67
EV to EBIT
30.12
EV to EBITDA
20.16
EV to Capital Employed
4.19
EV to Sales
4.44
PEG Ratio
1.49
Dividend Yield
NA
ROCE (Latest)
13.91%
ROE (Latest)
23.84%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
7,230.10
6,206.60
16.49%
Operating Profit (PBDIT) excl Other Income
1,352.40
1,345.40
0.52%
Interest
111.20
133.20
-16.52%
Exceptional Items
-2.80
0.00
Consolidate Net Profit
896.90
889.60
0.82%
Operating Profit Margin (Excl OI)
122.60%
151.30%
-2.87%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 16.49% vs 4.11% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 0.82% vs 47.46% in Dec 2024
About Shanghai Henlius Biotech, Inc. 
Shanghai Henlius Biotech, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






